{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:31:42Z","timestamp":1790746302086,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00380-025-02609-4","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T06:43:39Z","timestamp":1759819419000},"page":"246-257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative effectiveness of sodium zirconium cyclosilicate versus calcium polystyrene sulfonate for patients with heart failure"],"prefix":"10.1007","volume":"41","author":[{"given":"Hiroki","family":"Shimada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-4071","authenticated-orcid":false,"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2609_CR1","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/ajhp\/zxad137","volume":"80","author":"E Sullivan","year":"2023","unstructured":"Sullivan E, Ruegger M, Dunne I, Sutaria N, Towers WF (2023) Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients. Am J Health-Syst Pharm 80:1238\u20131246","journal-title":"Am J Health-Syst Pharm"},{"key":"2609_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/ckj\/sfab159","volume":"15","author":"M Trevisan","year":"2022","unstructured":"Trevisan M, Clase CM, Evans M, Popov T, Ludvigsson JF, Sj\u00f6lander A, Carrero JJ (2022) Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease. Clin Kidney J 15:153\u2013161","journal-title":"Clin Kidney J"},{"key":"2609_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12875-022-01667-1","volume":"23","author":"JB Muhlestein","year":"2022","unstructured":"Muhlestein JB, Kammerer J, Bair TL, Knowlton KU, Le VT, Anderson JL, Lapp\u00e9 DL, May HT (2022) Real-world clinical burden and economic assessment associated with hyperkalaemia in a large integrated healthcare system: a retrospective analysis. BMC Prim Care 23:65","journal-title":"BMC Prim Care"},{"key":"2609_CR4","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/ehf2.14661","volume":"11","author":"DE Grobbee","year":"2024","unstructured":"Grobbee DE, Filippatos G, Desai NR, Coats AJS, Pinto F, Rosano GMC, Cleland JGF, Kammerer J, de Arellano AR (2024) Epidemiology and risk factors for hyperkalaemia in heart failure. ESC Heart Fail 11:1821\u20131840","journal-title":"ESC Heart Fail"},{"key":"2609_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/clc.23392","volume":"43","author":"A Rakisheva","year":"2020","unstructured":"Rakisheva A, Marketou M, Klimenko A, Troyanova-Shchutskaia T, Vardas P (2020) Hyperkalemia in heart failure: foe or friend? Clin Cardiol 43:666\u2013675","journal-title":"Clin Cardiol"},{"key":"2609_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726","journal-title":"Eur Heart J"},{"key":"2609_CR7","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:1757\u20131780","journal-title":"J Am Coll Cardiol"},{"key":"2609_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1159\/000531102","volume":"54","author":"J An","year":"2023","unstructured":"An J, Zhou H, Ni L, Harrision TN, Wei R, Agiro A, Brahmbhatt YG, Oluwatosin Y, Schilling CG, Sim JJ (2023) Discontinuation of renin-angiotensin-aldosterone system inhibitors secondary to hyperkalemia translates into higher cardiorenal outcomes. Am J Nephrol 54:258\u2013267","journal-title":"Am J Nephrol"},{"key":"2609_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-002022","volume":"9","author":"A Jonsson Holmdahl","year":"2022","unstructured":"Jonsson Holmdahl A, Wessberg G, Norberg H, S\u00f6derstr\u00f6m A, Valham F, Bergdahl E, Lindmark K (2022) Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population. Open Heart 9:e002022","journal-title":"Open Heart"},{"key":"2609_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/ajh\/hpy101","volume":"31","author":"T Nishihara","year":"2018","unstructured":"Nishihara T, Tokitsu T, Sueta D, Takae M, Oike F, Fujisue K, Usuku H, Takashio S, Hanatani S, Kanazawa H, Arima Y, Sakamoto K, Izumiya Y, Yamabe H, Kaikita K, Yamamoto E, Tsujita K (2018) Serum potassium and cardiovascular events in heart failure with preserved left ventricular ejection fraction patients. Am J Hypertens 31:1098\u20131105","journal-title":"Am J Hypertens"},{"key":"2609_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ehf2.13164","volume":"8","author":"JB Muhlestein","year":"2021","unstructured":"Muhlestein JB, Kammerer J, Bair TL, Knowlton KU, Le VT, Anderson JL, Lapp\u00e9 DL, May HT (2021) Frequency and clinical impact of hyperkalaemia within a large, modern, real-world heart failure population. ESC Heart Fail 8:691\u2013696","journal-title":"ESC Heart Fail"},{"key":"2609_CR12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee APW, Linssen GCM, Llamas-Esper\u00f3n G, Mareev V, Martinez FA, Melenovsk\u00fd V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P, FINEARTS-HF Committees and Investigators (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475\u20131485","journal-title":"N Engl J Med"},{"key":"2609_CR13","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1253\/circj.CJ-25-0002","volume":"89","author":"T Kitai","year":"2025","unstructured":"Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, Yaku H, Akiyama E, Ando M, Izumi C, Ide T, Iwasaki YK, Ohno Y, Okumura T, Ozasa N, Kaji S, Kashimura T, Kitaoka H, Kinugasa Y, Kinugawa S, Toda K, Nagai T, Nakamura M, Hikoso S, Minamisawa M, Wakasa S, Anchi Y, Oishi S, Okada A, Obokata M, Kagiyama N, Kato NP, Kohno T, Sato T, Shiraishi Y, Tamaki Y, Tamura Y, Nagao K, Nagatomo Y, Nakamura N, Nochioka K, Nomura A, Nomura S, Horiuchi Y, Mizuno A, Murai R, Inomata T, Kuwahara K, Sakata Y, Tsutsui H, Kinugawa K, Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group (2025) JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure. Circ J 89:1278\u20131444","journal-title":"Circ J"},{"key":"2609_CR14","volume":"16","author":"ES Sinnathamby","year":"2024","unstructured":"Sinnathamby ES, Banh KT, Barham WT, Hernandez TD, De Witt AJ, Wenger DM, Klapper VG, McGregor D, Paladini A, Ahmadzadeh S, Shekoohi S, Kaye AD, Varrassi G (2024) Hyperkalemia: pharmacotherapies and clinical considerations. Cureus 16:e52994","journal-title":"Cureus"},{"key":"2609_CR15","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ekir.2019.05.018","volume":"4","author":"N Kashihara","year":"2019","unstructured":"Kashihara N, Kohsaka S, Kanda E, Okami S, Yajima T (2019) Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int Rep 4:1248\u20131260","journal-title":"Kidney Int Rep"},{"key":"2609_CR16","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B (2014) Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312:2223\u20132233","journal-title":"JAMA"},{"key":"2609_CR17","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.cardfail.2022.04.003","volume":"28","author":"M Zhuo","year":"2022","unstructured":"Zhuo M, Kim SC, Patorno E, Paik JM (2022) Risk of hospitalization for heart failure in patients with hyperkalemia treated with sodium zirconium cyclosilicate versus Patiromer. J Card Fail 28:1414\u20131423","journal-title":"J Card Fail"},{"key":"2609_CR18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","volume":"85","author":"MN Kosiborod","year":"2025","unstructured":"Kosiborod MN, Cherney DZI, Desai AS, Testani JM, Verma S, Chinnakondepalli K, Dolling D, Patel S, Dahl M, Eudicone JM, Friberg L, Ouwens M, Antunes MO, Connelly KA, Madrini V, Kuthi L, Lala A, Lorenzo M, Guimar\u00e3es PO, Marcos MC, Merkely B, Nu\u00f1ez J, Squire I, V\u00e1clav\u00edk J, Wranicz J, Petrie MC (2025) Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure. J Am Coll Cardiol 85:971\u2013984","journal-title":"J Am Coll Cardiol"},{"key":"2609_CR19","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F, Pi\u00f1a IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P (2015) Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 17:1050\u20131056","journal-title":"Eur J Heart Fail"},{"key":"2609_CR20","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ehf2.14268","volume":"10","author":"J-C Tardif","year":"2023","unstructured":"Tardif J-C, Rouleau J, Chertow GM, Al-Shurbaji A, Lisovskaja V, Gustavson S, Zhao Y, Bouabdallaoui N, Desai AS, Chernyavskiy A, Evsina M, Merkely B, McMurray JJV, Pfeffer MA (2023) Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Fail 10:1066\u20131076","journal-title":"ESC Heart Fail"},{"key":"2609_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jgf2.367","volume":"21","author":"K Nagai","year":"2020","unstructured":"Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T (2020) Data resource profile: JMDC claims databases sourced from medical institutions. J Gen Fam Med 21:211\u2013218","journal-title":"J Gen Fam Med"},{"key":"2609_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70063","volume":"33","author":"T Anno","year":"2024","unstructured":"Anno T, Fukasawa T, Shinozaki T, Takeuchi M, Yoshida S, Kawakami K (2024) Impact of early resumption of oral anticoagulation on recurrence after surgery for chronic subdural hematoma in patients with atrial fibrillation: a target trial emulation. Pharmacoepidemiol Drug Saf 33:e70063","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2609_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11657-024-01428-w","volume":"19","author":"S Masuda","year":"2024","unstructured":"Masuda S, Fukasawa T, Otsuki B, Murata K, Shimizu T, Sono T, Honda S, Shima K, Sakamoto M, Matsuda S, Kawakami K (2024) Unchanged incidence of major adverse events amidst rising surgical interventions for osteoporotic vertebral fractures, 2015\u20132021. Arch Osteoporos 19:71","journal-title":"Arch Osteoporos"},{"key":"2609_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/endrev\/bnab007","volume":"42","author":"S Schneeweiss","year":"2021","unstructured":"Schneeweiss S, Patorno E (2021) Conducting real-world evidence studies on the clinical outcomes of diabetes treatments. Endocr Rev 42:658\u2013690","journal-title":"Endocr Rev"},{"key":"2609_CR25","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s00198-024-07255-6","volume":"35","author":"S Masuda","year":"2024","unstructured":"Masuda S, Fukasawa T, Matsuda S, Yoshida S, Kawakami K (2024) Comparative effectiveness and cardiovascular safety of Romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study. Osteoporos Int 35:2165\u20132174","journal-title":"Osteoporos Int"},{"key":"2609_CR26","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1681\/ASN.2016121344","volume":"28","author":"JR Montford","year":"2017","unstructured":"Montford JR, Linas S (2017) How dangerous is hyperkalemia? J Am Soc Nephrol 28:3155\u20133165","journal-title":"J Am Soc Nephrol"},{"key":"2609_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.7326\/ANNALS-24-03237","volume":"178","author":"S Masuda","year":"2025","unstructured":"Masuda S, Fukasawa T, Matsuda S, Kawakami K (2025) Cardiovascular safety and fracture prevention effectiveness of denosumab versus oral bisphosphonates in patients receiving dialysis: a target trial emulation. Ann Intern Med 178:167\u2013176","journal-title":"Ann Intern Med"},{"key":"2609_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14119","volume":"54","author":"H Tada","year":"2024","unstructured":"Tada H, Kaneko H, Suzuki Y, Okada A, Takeda N, Fujiu K, Morita H, Ako J, Node K, Takeji Y, Takamura M, Yasunaga H, Komuro I (2024) Familial hypercholesterolemia is related to cardiovascular disease, heart failure and atrial fibrillation. Results from a population-based study. Eur J Clin Invest 54:e14119","journal-title":"Eur J Clin Invest"},{"key":"2609_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006021","author":"MD Ritchey","year":"2017","unstructured":"Ritchey MD, Loustalot F, Wall HK, Steiner CA, Gillespie C, George MG, Wright JS (2017) Million Hearts: description of the national surveillance and modeling methodology used to monitor the number of cardiovascular events prevented during 2012\u20132016. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.117.006021","journal-title":"J Am Heart Assoc"},{"key":"2609_CR30","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/pds.5213","volume":"30","author":"K Fujihara","year":"2021","unstructured":"Fujihara K, Yamada-Harada M, Matsubayashi Y, Kitazawa M, Yamamoto M, Yaguchi Y, Seida H, Kodama S, Akazawa K, Sone H (2021) Accuracy of Japanese claims data in identifying diabetes-related complications. Pharmacoepidemiol Drug Saf 30:594\u2013601","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2609_CR31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M18-3079","volume":"170","author":"S Schneeweiss","year":"2019","unstructured":"Schneeweiss S, Rassen JA, Brown JS, Rothman KJ, Happe L, Arlett P, Dal Pan G, Goettsch W, Murk W, Wang SV (2019) Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med 170:398\u2013406","journal-title":"Ann Intern Med"},{"key":"2609_CR32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/pds.5071","volume":"29","author":"A Weisman","year":"2020","unstructured":"Weisman A, King LK, Mamdani M (2020) Reporting and variability of constructing medication treatment episodes in pharmacoepidemiology studies: a methodologic systematic review using the case study of DPP-4 inhibitors and cardiovascular outcomes. Pharmacoepidemiol Drug Saf 29:939\u2013950","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2609_CR33","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34:3661\u20133679","journal-title":"Stat Med"},{"key":"2609_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5657","volume":"367","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Franklin JM (2019) Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 367:l5657","journal-title":"BMJ"},{"key":"2609_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","volume":"13","author":"S Xu","year":"2010","unstructured":"Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D (2010) Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13:273\u2013277","journal-title":"Value Health"},{"key":"2609_CR36","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083\u20133107","journal-title":"Stat Med"},{"key":"2609_CR37","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/EDE.0000000000001023","volume":"30","author":"T Shinozaki","year":"2019","unstructured":"Shinozaki T, Nojima M (2019) Misuse of regression adjustment for additional confounders following insufficient propensity-score balancing. Epidemiology 30:541\u2013548","journal-title":"Epidemiology"},{"key":"2609_CR38","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","volume":"48","author":"P Peduzzi","year":"1995","unstructured":"Peduzzi P, Concato J, Feinstein AR, Holford TR (1995) Importance of events per independent variable in proportional hazards regression analysis. Part II. Accuracy and precision of regression estimates. J Clin Epidemiol 48:1503\u20131510","journal-title":"J Clin Epidemiol"},{"key":"2609_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae021","volume":"17","author":"C Onogi","year":"2024","unstructured":"Onogi C, Watanabe Y, Tanaka A, Furuhashi K, Maruyama S (2024) Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium\/calcium polystyrene sulfonate. Clin Kidney J 17:sfae021","journal-title":"Clin Kidney J"},{"key":"2609_CR40","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, Friede T, Fabien V, Kosiborod M, Metra M, Pi\u00f1a IL, Pinto F, Rossignol P, van der Meer P, Bahit C, Belohlavek J, B\u00f6hm M, Brugts JJ, Cleland JGF, Ezekowitz J, Bayes-Genis A, Gotsman I, Goudev A, Khintibidze I, Lindenfeld J, Mentz RJ, Merkely B, Montes EC, Mullens W, Nicolau JC, Parkhomenko A, Ponikowski P, Seferovic PM, Senni M, Shlyakhto E, Cohen-Solal A, Szecs\u00f6dy P, Jensen K, Dorigotti F, Weir MR, Pitt B (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 43:4362\u20134373","journal-title":"Eur Heart J"},{"key":"2609_CR41","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, PEARL-HF Investigators (2011) Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32:820\u2013828","journal-title":"Eur Heart J"},{"key":"2609_CR42","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/ejhf.1860","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol P, Williams B, Mayo MR, Warren S, Arthur S, Ackourey G, White WB, Agarwal R (2020) Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. Eur J Heart Fail 22:1462\u20131471","journal-title":"Eur J Heart Fail"},{"key":"2609_CR43","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10741-025-10490-6","volume":"30","author":"L Monzo","year":"2025","unstructured":"Monzo L, Musella F, Girerd N, Rossignol P (2025) Sodium zirconium cyclosilicate for MRAs optimization in HFrEF: lessons learned from the REALIZE-K trial. Heart Fail Rev 30:565\u2013574","journal-title":"Heart Fail Rev"},{"key":"2609_CR44","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Mu\u00f1oz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B (2019) 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 140:e596\u2013e646","journal-title":"Circulation."},{"key":"2609_CR45","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, Barany P, Jernberg T, Lund LH, Carrero JJ (2018) Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail 20:1217\u20131226","journal-title":"Eur J Heart Fail"},{"key":"2609_CR46","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.2287","volume":"23","author":"M Trevisan","year":"2021","unstructured":"Trevisan M, Fu EL, Xu Y, Savarese G, Dekker FW, Lund LH, Clase CM, Sj\u00f6lander A, Carrero JJ (2021) Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail 23:1698\u20131707","journal-title":"Eur J Heart Fail"},{"key":"2609_CR47","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3945\/ajcn.110.000174","volume":"93","author":"J Arcand","year":"2011","unstructured":"Arcand J, Ivanov J, Sasson A, Floras V, Al-Hesayen A, Azevedo ER, Mak S, Allard JP, Newton GE (2011) A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study. Am J Clin Nutr 93:332\u2013337","journal-title":"Am J Clin Nutr"},{"key":"2609_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321","journal-title":"N Engl J Med"},{"key":"2609_CR49","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O\u2019Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, Investigators TOPCAT (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383\u20131392","journal-title":"N Engl J Med"},{"key":"2609_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa1803180","volume":"381","author":"AC Flint","year":"2019","unstructured":"Flint AC, Conell C, Ren X, Banki NM, Chan SL, Rao VA, Melles RB, Bhatt DL (2019) Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med 381:243\u2013251","journal-title":"N Engl J Med"},{"key":"2609_CR51","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1161\/STROKEAHA.117.018148","volume":"48","author":"LS Johnson","year":"2017","unstructured":"Johnson LS, Mattsson N, Sajadieh A, Wollmer P, S\u00f6derholm M (2017) Serum potassium is positively associated with stroke and mortality in the large, population-based Malm\u00f6 preventive project cohort. Stroke 48:2973\u20132978","journal-title":"Stroke"},{"key":"2609_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010057","volume":"16","author":"X Cai","year":"2022","unstructured":"Cai X, Li N (2022) Association between use of spironolactone and risk of stroke in hypertensive patients: a cohort study. Pharmaceuticals (Basel) 16:57","journal-title":"Pharmaceuticals (Basel)"},{"key":"2609_CR53","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00380-023-02296-z","volume":"39","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wan Y, Karunathilaka N, Chan W, Kostner K, Hartel G, Coats AJS, Atherton JJ, Punyadeera C (2024) Prognostic utility of serum NT-proBNP (fragments 1\u201376aa and 13\u201371aa) and galectin-3 in predicting death and re-hospitalisation due to cardiovascular events in patients with heart failure. Heart Vessels 39:86\u201394","journal-title":"Heart Vessels"},{"key":"2609_CR54","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00380-024-02486-3","volume":"40","author":"K Izumi","year":"2025","unstructured":"Izumi K, Kohno T, Goda A, Takeuchi S, Shiraishi Y, Higuchi S, Nakamaru R, Nagatomo Y, Kitamura M, Takei M, Sakamoto M, Mizuno A, Nomoto M, Soejima K, Kohsaka S, Yoshikawa T (2025) Effect of basic activities of daily living independence on home discharge and long-term outcomes in patients hospitalized with heart failure. Heart Vessels 40:471\u2013483","journal-title":"Heart Vessels"},{"key":"2609_CR55","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/ndt\/gfae056","volume":"39","author":"BF Palmer","year":"2024","unstructured":"Palmer BF, Clegg DJ (2024) Hyperkalemia treatment standard. Nephrol Dial Transplant 39:1097\u20131104","journal-title":"Nephrol Dial Transplant"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-025-02609-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-025-02609-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-025-02609-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:02:06Z","timestamp":1774555326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-025-02609-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2609"],"URL":"https:\/\/doi.org\/10.1007\/s00380-025-02609-4","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kayoko Mizuno had been employed by the Department of Digital Health and Epidemiology, which receives support from Eisai Co., Ltd. and Kyowa Kirin Co., Ltd. Koji Kawakami receives research funding from AstraZeneca, Eisai Co., Ltd., Kyowa Kirin Co., Ltd., OMRON Corporation, and Toppan Inc.; consulting fees from Advanced Medical Care Inc., JMDC Inc., Shin Nippon Biomedical Laboratories Ltd., and Ubicom Holdings Inc.; executive compensation from Cancer Intelligence Care Systems, Inc. and Mytreya Inc.; and honoraria from Pharma Business Academy Co., Ltd. and SANSHO Co., Ltd.\u3000The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol adhered to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the Kyoto University Graduate School and Faculty of Medicine (No. R4615).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As all data were anonymized prior to analysis, the requirement for individual informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}